Tumor-Specific T-Cells (cCTL:GL01) for Advanced Gastrointestinal Cancer

NCT07735065 | Not Yet Recruiting Phase 1 DMC

• 1 other identifier: SC2026-0005-02
• Study Type: interventional
• Target: 20
• Locations: 0 countries
• Sites: N/A

Brief Summary

This clinical trial is designed to study an investigational cell therapy called cCTL-GL01 in patients with advanced gastrointestinal cancers (including cancers of the stomach, esophagus, colon, or rectum) that have not responded well to standard treatments. The main goals of this study are to find out: If cCTL-GL01 is safe and what side effects it might cause; How well cCTL-GL01 works to control or shrink tumors.

Conditions

Advanced Gastrointestinal Cancer

Keywords

Tumor specific T cell; Cell Therapy; Gastrointestinal Cancer

Outcome Measures

Primary Outcomes (1)

• dose-limiting toxicities (DLTs)

  To evaluate safety, the investigator will monitor the number of participants experiencing treatment-related adverse events (AEs) and dose-limiting toxicities (DLTs), assessing their incidence, type, severity, and causality. All AEs, including immunotherapy-related reactions such as cytokine release syndrome (CRS), will be graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0. The primary parameters to be evaluated are as follows: ①Blood pressure: Changes in patients' blood pressure will be closely monitored throughout the treatment. The measurement data will be reported and aggregated in millimeters of mercury (mmHg). ②Pulse: Patients' pulse will be continuously monitored throughout the trial to evaluate physiological stability and acute reactions following treatment administration. The measurement data will be reported in beats per minute (bpm). ③Inflammatory Markers: Blood inflammatory markers, specifically C-reactive prote

  From Week 1 through Week 16 of treatment

Secondary Outcomes (5)

• Objective response rate (ORR)

  Up to Week 16 post-treatment (with imaging assessments up to approximately 12 months or until disease progression)

• disease control rate (DCR)

  Up to Week 16 post-treatment (with imaging assessments up to approximately 12 months or until disease progression)

• Progression-free survival (PFS)

  Up to approximately 24 months.

• overall survival (OS)

  Up to approximately 24 months.

• duration of response (DOR)

  Up to approximately 24 months.

Study Arms (1)

cCTL:GL01 Injection group

EXPERIMENTAL

Patients received i.v. infusion of cCTL:GL01

Drug: Biological/Vaccine

Interventions

Biological/Vaccine DRUG

Following lymphodepleting conditioning and a 2-3 day chemotherapy washout period, patients will begin receiving twice-weekly infusions of autologous cCTL cells. This study is designed such that the first three cCTL infusions for each patient will follow a stepwise dose escalation of the effective dose, specifically 1-2×107 cCTL/Kg、3-4×107 cCTL/Kg、4-5×107 cCTL/Kg; safety will be evaluated during this period to determine subsequent infusion doses. The target dose for this study is 4-5x107 cCTL/Kg per infusion, with a target frequency of twice weekly. This phase will last 2-3 weeks, with a total of 4-6 infusions. Based on the results of the first course of treatment, the investigator will determine whether to proceed with a second course of treatment. During treatment intervals, the investigator may administer bridging therapy based on the patient's clinical condition.

cCTL:GL01 Injection group

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age 18 to 65 years (inclusive), male or female;
• Ability to understand the study and has signed the written Informed Consent Form (ICF), and is willing and able to comply with all protocol-required procedures;
• Fresh tumor tissue samples can be obtained via biopsy or surgery, and peripheral blood mononuclear cells (PBMCs) can be obtained via apheresis;
• Histologically and/or cytologically confirmed advanced gastrointestinal solid tumors (e.g., esophageal cancer, gastric cancer, colon cancer, etc.), with previous receipt of at least one systemic therapy that failed or resulted in recurrence; OR previous receipt of any form of immunotherapy or cellular therapy that failed or resulted in recurrence;
• Presence of at least one measurable lesion according to RECIST v1.1, or has an evaluable target lesion/disease assessment method as determined by the investigator. (Note: A measurable lesion is defined as a non-nodal lesion with at least one dimension ≥ 10 mm, or a nodal lesion with a short axis ≥ 15 mm, measured by CT/MRI; lesions previously treated with local therapies \[e.g., radiotherapy\] cannot be considered as target lesions unless clear disease progression is documented.)
• Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 1;
• Life expectancy ≥ 20 weeks;
• Hepatitis B virus (HBV) infected patients (with HBV DNA levels below the lower limit of detection \[LLOD\]), or cured Hepatitis C virus (HCV) infected patients;
• Laboratory values within 14 days prior to the first dose of study drug must meet the following criteria:
• Hematology: Absolute neutrophil count (ANC) ≥1.5×109/L; Platelets (PLT) ≥100×109/L; Hemoglobin (Hb) ≥90g/L; Note: The above requirements must be met without receiving any transfusion of blood components or supportive therapy with cell growth factors within two weeks prior to blood collection.
• Renal Function: Serum creatinine ≤1.5×upper limit of normal (ULN) OR creatinine clearance (CrCl) ≥50mL/min (calculated using the Cockcroft-Gault formula).
• Hepatic Function: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.0×ULN (for patients with liver metastases, ALT and AST ≤3.0×ULN); Serum total bilirubin (TBIL) ≤1.5×ULN.
• Coagulation Function: International Normalized Ratio (INR) or prothrombin time (PT) ≤1.5×ULN (for patients receiving warfarin anticoagulation, INR must be between 1.5 and 2.5); activated partial thromboplastin time (aPTT) ≤1.5×ULN.
• Female patients of childbearing potential must have a confirmed negative serum pregnancy test within 3 days prior to the first dose of study drug, and must initiate effective contraception immediately following the negative result; patients of childbearing potential and their partners must agree to use highly effective contraception throughout the study drug treatment period and for 90 days after the last dose of study drug.
• Adverse events (AEs) related to prior anti-cancer therapy must have resolved to Grade 0 or 1; the following AEs are permitted for enrollment: alopecia, Grade ≤2 sensory neuropathy, and endocrine disorders controlled by hormone replacement therapy.

You may not qualify if:

• History of a second primary malignancy within 5 years (inclusive) prior to screening, except for cured cervical carcinoma in situ, localized skin squamous cell carcinoma, basal cell carcinoma, ductal carcinoma in situ (DCIS) of the breast, \<T1 urothelial carcinoma, or prostate cancer under active surveillance;
• Patients with Gilbert's syndrome;
• Patients with anorexia, nausea, or vomiting of Grade≥2;
• History of bowel obstruction or intestinal perforation within 6 months prior to screening;
• Patients who experienced Grade≥3 toxicity related to prior irinotecan use;
• Symptomatic brain metastases or leptomeningeal metastases; or other evidence indicating that central nervous system (CNS) metastases or leptomeningeal metastases are uncontrolled, and the investigator deems the patient unsuitable for enrollment. Patients with asymptomatic brain metastases or those stable after treatment (receiving≤10mg/day of prednisone or equivalent systemic corticosteroids), with both imaging and neurological examinations judged to be stable following relevant treatment, are permitted to be enrolled;
• History of cerebrovascular accident (CVA), transient ischemic attack (TIA), myocardial infarction (MI), unstable angina, or New York Heart Association (NYHA) Class III or IV heart failure within 24 weeks prior to enrollment; history of malignant arrhythmia within 12 weeks prior to enrollment; or QTcF \> 450 ms in males or QTcF \> 470 ms in females;
• Active autoimmune disease, or a history of autoimmune disease requiring systemic treatment within 2 years prior to screening. The following conditions are permitted for enrollment: hypothyroidism, vitiligo, Graves' ophthalmopathy, Hashimoto's thyroiditis, Type I diabetes mellitus, childhood asthma, or allergic asthma with no acute exacerbations/attacks within 2 years prior to screening;
• Prior history of allogeneic stem cell transplantation or solid organ transplantation;
• History of severe allergic reactions, Grade 3-4 hypersensitivity to humanized antibody or fusion protein therapies, or known hypersensitivity to irinotecan;
• History of Grade 3-4 immune-related adverse events (irAEs) or those leading to permanent discontinuation of treatment (except for Grade 3 endocrine abnormalities controlled by hormone replacement therapy);
• Receipt of \>10mg/day of prednisone (or equivalent systemic corticosteroids) or other immunosuppressants for≥5 consecutive days within 2 weeks prior to screening; however, short-course (≤1 week) of topical, ocular, intra-articular, intranasal, or inhaled administration is permitted;
• Receipt of any live vaccine within 4 weeks prior to enrollment;
• Presence of any of the following: Active bacterial infection requiring intravenous anti-infective therapy within 2 weeks prior to the first dose of study drug; Positive for human immunodeficiency virus (HIV) (HIV-1/2 antibodies); Active tuberculosis (TB) currently receiving anti-TB treatment or having received anti-TB treatment within 1 year prior to screening;
• Receipt of anti-cancer therapy or radiotherapy within 4 weeks or 5 half-lives (whichever is longer) prior to enrollment. Palliative radiotherapy for symptom control is permitted but must be completed at least 2 weeks prior to the first dose of study drug, and no additional radiotherapy is planned for the same lesions;

Sponsors & Collaborators

• The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School: lead

MeSH Terms

Conditions

Gastrointestinal Neoplasms

Interventions

Biological Products; Vaccines

Condition Hierarchy (Ancestors)

Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Digestive System Diseases; Gastrointestinal Diseases

Intervention Hierarchy (Ancestors)

Complex Mixtures

Central Study Contacts

Liu

CONTACT

+86 025-83106666; liuqin@nju.edu.cn

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 14, 2026
• First Posted: July 29, 2026
• Study Start: August 1, 2026
• Primary Completion (Estimated): August 1, 2028
• Study Completion (Estimated): August 1, 2028
• Last Updated: July 29, 2026

Record last verified: 2026-07